UroToday7h
ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer
The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...
UroToday1d
ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy
The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...
UroToday1d
ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)
Dr. Gopakumar Iyer discussed how to Integrate Novel Therapeutics with trimodal therapy (TMT). Radiation therapy (RT) has ...
UroToday23h
ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer
(UroToday.com) The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and October 2 was host to the session EDU 16 - Management of ...
UroToday1d
ASTRO 2024: Strategies and Evidence for SABR in RCC
(UroToday.com) The 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting held in Washington, DC between September 29 th and October 2 nd, 2024, was host to a presidential symposium of ...
UroToday4d
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer - Beyond the Abstract
Managing biochemically recurrent prostate cancer is challenging when conventional imaging like CT and MRI fails to identify recurrent disease, particularly at low PSA levels. Treatment can be given ...
UroToday4d
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer.
Introduction: Neuroendocrine/small-cell prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer, which typically develops after prolonged treatment ...
UroToday5d
Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System - Beyond the Abstract
Our research, titled "Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System," analyzed follow-up patterns for over 28,000 ...
UroToday4d
Evaluating the Impact of a Shared Decision-making Intervention for Patients with Renal Cell Carcinoma: The SDM-RCC Study Protocol.
The aim of the SDM-RCC study is to evaluate the impact of a comprehensive shared decision-making (SDM) intervention for patients with renal cell carcinoma (RCC) on the decision-making process and ...
UroToday4d
Perioperative and Extended Outcomes of Patients Undergoing Parastomal Hernia Repair Following Cystectomy and Ileal Conduit - Beyond the Abstract
Radical cystectomy (RC) with urinary diversion remains the gold standard for muscle-invasive bladder cancer as well as high-risk non-invasive variants, with a higher proportion of patients receiving ...
UroToday5d
Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.
Patients who undergo primary retroperitoneal lymph node dissection (pRPLND) for early-stage testicular cancer and have no cancer (pN0) found in the retroperitoneum are believed to have an excellent ...
UroToday5d
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the ...